Mackay Shields LLC Has $3.28 Million Position in Catalent, Inc. (NYSE:CTLT)

Mackay Shields LLC lowered its stake in shares of Catalent, Inc. (NYSE:CTLTGet Rating) by 1.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 25,600 shares of the company’s stock after selling 482 shares during the period. Mackay Shields LLC’s holdings in Catalent were worth $3,277,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in CTLT. BlackRock Inc. raised its position in Catalent by 0.3% in the third quarter. BlackRock Inc. now owns 14,370,233 shares of the company’s stock worth $1,912,246,000 after purchasing an additional 46,136 shares in the last quarter. Capital World Investors raised its position in Catalent by 10.6% in the third quarter. Capital World Investors now owns 10,632,004 shares of the company’s stock worth $1,414,801,000 after purchasing an additional 1,018,902 shares in the last quarter. Geode Capital Management LLC raised its position in Catalent by 2.0% in the third quarter. Geode Capital Management LLC now owns 2,994,717 shares of the company’s stock worth $397,433,000 after purchasing an additional 58,270 shares in the last quarter. Third Point LLC raised its position in Catalent by 12.2% in the third quarter. Third Point LLC now owns 1,375,000 shares of the company’s stock worth $182,971,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Allianz Asset Management GmbH raised its position in Catalent by 136.9% in the third quarter. Allianz Asset Management GmbH now owns 1,347,590 shares of the company’s stock worth $179,324,000 after purchasing an additional 778,781 shares in the last quarter. 93.81% of the stock is owned by institutional investors and hedge funds.

CTLT has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Catalent from $129.00 to $110.00 and set a “hold” rating for the company in a research report on Tuesday, April 12th. Barclays dropped their price objective on shares of Catalent from $160.00 to $130.00 and set an “overweight” rating for the company in a report on Thursday, January 27th. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “strong-buy” rating and set a $143.00 price objective for the company in a report on Tuesday, January 4th. StockNews.com began coverage on shares of Catalent in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Morgan Stanley dropped their price objective on shares of Catalent from $160.00 to $145.00 and set an “overweight” rating for the company in a report on Wednesday, February 2nd. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Catalent currently has an average rating of “Buy” and an average target price of $142.88.

In other news, CAO Ricky Hopson sold 2,325 shares of Catalent stock in a transaction on Monday, January 31st. The shares were sold at an average price of $103.39, for a total transaction of $240,381.75. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Peter Zippelius sold 487,092 shares of Catalent stock in a transaction on Sunday, February 6th. The stock was sold at an average price of $102.65, for a total transaction of $49,999,993.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 489,601 shares of company stock worth $50,259,212. Insiders own 0.53% of the company’s stock.

CTLT opened at $97.32 on Monday. Catalent, Inc. has a one year low of $91.17 and a one year high of $142.64. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.85 and a quick ratio of 2.19. The company’s 50 day simple moving average is $103.21 and its 200-day simple moving average is $115.80. The stock has a market capitalization of $17.43 billion, a P/E ratio of 30.04, a price-to-earnings-growth ratio of 1.66 and a beta of 1.38.

Catalent (NYSE:CTLTGet Rating) last announced its quarterly earnings data on Tuesday, February 1st. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.06. Catalent had a net margin of 12.94% and a return on equity of 14.93%. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same period last year, the firm earned $0.58 earnings per share. The business’s revenue for the quarter was up 33.6% on a year-over-year basis. As a group, analysts anticipate that Catalent, Inc. will post 3.48 EPS for the current year.

Catalent Profile (Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.

See Also

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLTGet Rating).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.